COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,761 Articles (22,502 medRxiv, 8,259 bioRxiv)

Most recent first Previous |  Page 1292: Articles 12911-12920  | Next

A significant increase in Tuberculosis diagnosis is required to mitigate the impact of COVID-19 on its future burden
Tovar, M., Aleta, A., Sanz, J., Moreno, Y.
10.1101/2021.07.24.21261074 — Posted: 2021-07-27
Executable Network of SARS-CoV-2-Host Interaction Predicts Drug Combination Treatments
Howell, R., Clarke, M. A., Reuschl, A.-K., Chen, T., Abott-Imboden, S., Singer, M., Lowe, D. M., Bennett, C. L., Chain, B., Jolly, C., Fisher, J.
10.1101/2021.07.27.453973 — Posted: 2021-07-27
Molecular Pathophysiology of Cardiac Injury and Cardiac Microthrombi in Fatal COVID-19: Insights from Clinico-histopathologic and Single Nuclei RNA Sequencing Analyses
Fukuma, N., Hulke, M. L., Brener, M. I., Golob, S., Zilinyi, R., Zhou, Z., Tzimas, C., Russo, I., McGroder, C., Pfeiffer, R., Chong, A., Zhang, G., Burkhoff, D., Leon, M. B., Maurer, M., Moses, J. W., Uhlemann, A.-C., Hibshoosh, H., Uriel, N., Szabolcs, M. J., Redfors, B., Marboe, C. C., Baldwin, M. R., Tucker, N. R., Tsai, E. J.
10.1101/2021.07.27.453843 — Posted: 2021-07-27
Site-specific recognition of SARS-CoV-2 nsp1 protein with a tailored titanium dioxide nanoparticle
Agback, P., Agback, T., Dominguez, F., Frolova, E. I., Seisenbaeva, G., Kessler, V.
10.1101/2021.07.27.453834 — Posted: 2021-07-27
Understanding SARS-CoV-2 budding through molecular dynamics simulations of M and E protein complexes
Collins, L. T., Elkholy, T., Mubin, S., Williams, R., Ezike, K., Singhal, A.
10.1101/2021.07.26.453874 — Posted: 2021-07-27
High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020
Dub, T., Nohynek, H., Hagberg, L., Liedes, O., Haveri, A., Virta, C., Solastie, A., Vara, S., Ekstrom, N., Osterlund, P., Lind, K., Valtonen, H., Hemmila, H., Ikonen, N., Lukkarinen, T. J., Palmu, A. A., Melin, M.
10.1101/2021.07.25.21260925 — Posted: 2021-07-27
Plasma oxylipin levels may predict Covid-19 patient outcomes. An observational and retrospective study.
Biagini, D., Franzini, M., Oliveri, P., Lomonaco, T., Ghimenti, S., Bonini, A., Vivaldi, F., Macera, L., Balas, L., Durand, T., Oger, C., Galano, J.-M., Maggi, F., Celi, A., Paolicchi, A., Di Francesco, F.
10.1101/2021.07.21.21260954 — Posted: 2021-07-27
A Partition-Based Group Testing Algorithm for Estimating the Number of Infected Individuals
Beigel, R., Webber, M. J.
10.1101/2021.07.27.21260924 — Posted: 2021-07-27
Effect of Balloon-Blowing on Dyspnea and Oxygenation in Noncritical Adult Covid19 Patients: A Pilot Study
Bargahi, M., Soltani, S., Rastgoo, N., Aryanejad, F., Esmaielzade, S., Nemati, R., Ghaebi, M., Bajelan, A.
10.1101/2021.07.27.21260398 — Posted: 2021-07-27
Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Parikh, D., Chaturvedi, A., Shah, N., Patel, P., Patel, R., Ray, S.
10.1101/2021.07.26.21261119 — Posted: 2021-07-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).